• Recently, investors reacted to concerns that CooperCompanies’ expected annual revenue growth may trail healthcare peers, alongside scrutiny of its below-average returns on capital.
• This shift in sentiment highlights how efficiently CooperCompanies allocates capital is becoming just as important as its topline growth prospects.
• We’ll now examine how worries about slower revenue growth relative to peers could influence CooperCompanies’ previously optimistic investment narrative.

Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

Cooper Companies Investment Narrative Recap

To own CooperCompanies, you need to believe its mix of contact lenses and women’s health products can compound value even if headline growth is only mid single digit. The latest concerns about slower revenue growth and muted returns on capital directly challenge that view, but they do not yet appear to change the immediate catalyst, which is whether MyDAY’s ramp and improving CooperSurgical trends can translate into cleaner, more profitable growth. The biggest near term risk remains execution in a slower contact lens market.

The recent guidance update for FY 2026, calling for organic revenue growth of about 3.5% to 4.5%, is especially relevant to these worries about lagging peers. It underlines that expectations were already moderate and puts more focus on how efficiently CooperCompanies converts incremental sales into earnings and free cash flow. Against this backdrop, the ongoing share repurchase program, including more than US$1.1 billion spent cumulatively, matters mainly if underlying returns on capital improve from here.

Yet beneath the growth story, there is a less visible risk in how slower demand and pricing pressure could interact with already modest returns on equity that investors should be aware of...

Cooper Companies' narrative projects $4.9 billion revenue and $817.1 million earnings by 2029. This requires 5.1% yearly revenue growth and an earnings increase of about $581 million from $235.8 million today.

Uncover how Cooper Companies' forecasts yield a $80.57 fair value, a 22% upside to its current price.

Exploring Other Perspectives

More pessimistic analysts were already assuming only about 4.5% annual revenue growth and roughly US$808.6 million of earnings by 2029, so this slowdown could push their already cautious view even further.

Explore 5 other fair value estimates on Cooper Companies - why the stock might be worth 34% less than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Cooper Companies research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Cooper Companies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Cooper Companies' overall financial health at a glance.

Looking For Alternative Opportunities?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• AI is about to change healthcare. These 38 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• This technology could replace computers: discover 30 stocks that are working to make quantum computing a reality.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.